€0.38
Your prediction
Sangamo Therapeutics Inc. Stock
Pros and Cons of Sangamo Therapeutics Inc. in the next few years
Pros
Cons
Performance of Sangamo Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Sangamo Therapeutics Inc. | 0.100% | -9.647% | -6.341% | -78.789% | -84.217% | -88.458% | -96.210% |
| Ardelyx Inc. | 5.570% | 2.840% | 1.187% | 5.509% | 6.465% | 176.349% | -3.856% |
| Krystal Biotech | 0.330% | 3.678% | 18.962% | 25.776% | 37.057% | 193.803% | - |
| Evolus Inc | -4.200% | -1.724% | -8.065% | -47.706% | -45.714% | -18.571% | 88.742% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Evaluating the financials of Sangamo Therapeutics (SGMO) offers insight into a company navigating the complex and often turbulent waters of the biotechnology and medical research industry. The company currently showcases a mix of challenges, primarily characterized by significant operating losses, cash flow struggles, and a negative net income trajectory. However, there are aspects worth highlighting, including its valuation metrics and market positioning, indicating potential future growth opportunities.
Market Capitalization: With a market capitalization of approximately $156.49 million, Sangamo Therapeutics is still seen as a valuable player within the biotechnology sector. A solid market capitalization can provide some stability and attracts institutional interest, which is crucial for long-term growth.
Book Value: The book value per share is $0.278, which practically offers a gauge for investors to assess whether the stock price aligns with the company's assets. If the market perceives the stock as undervalued compared to its book value, it could signal potential for price appreciation.
Comments
News
Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced positive topline results from the registrational Phase 1/2 STAAR study evaluating isaralgagene civaparvovec
